BPC-157 + TB-500 + GHK-Cu + KPV

A multi-peptide research blend examined across extracellular matrix dynamics, inflammatory signaling, angiogenesis, and cell migration models.

View KLOW in the store

Molecular Profile

Type
Peptide blend

Components

GHK-Cu

Molecular formula
C14H24CuN6O4
Molecular weight
~403.9 g/mol
CAS number
89030-95-5
Sequence
Gly-His-Lys + Cu(II)

KPV

Molecular formula
C16H30N4O4
Molecular weight
342.43 g/mol
CAS number
67727-97-3
Sequence
Lys-Pro-Val

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1,419.5 g/mol
CAS number
137525-51-0
Sequence
GEPPPGKPADDAGLV

TB-500

Molecular formula
C38H68N10O14
Molecular weight
889.02 g/mol
CAS number
885340-08-9
Sequence
Ac-LKKTETQ

Mechanism & Target Class

A four-component formulation combining a copper-binding tripeptide (GHK-Cu), an alpha-MSH-derived tripeptide (KPV), a gastric-juice-derived pentadecapeptide (BPC-157), and a synthetic heptapeptide corresponding to the actin-binding domain of Thymosin Beta-4 (TB-500, Ac-LKKTETQ). The components engage distinct molecular targets: GHK-Cu modulates ECM gene expression; KPV acts through NF-κB-associated inflammatory pathways; BPC-157 interacts with the nitric oxide system and VEGFR2; TB-500 sequesters actin to influence cell migration via PI3K/Akt/eNOS signaling. No unified receptor target governs the blend.

Storage & Handling

Lyophilized
-20°C; protect from light; stable months desiccated.
Handling
GHK-Cu component is sensitive to alkaline pH; peptides are sensitive to heat, light, and agitation; blend ratios vary by supplier.

References (17)

  1. Reviews

    1

    McGuire F, Hughes E, Maak T, Cushman DM (2026). Preprints.org

    DOI: 10.20944/preprints202605.1124.v1

  2. 2

    Rahman OF, Lee SJ, Seeds WA (2026). JAAOS Global Research & Reviews

    DOI: 10.5435/JAAOSGlobal-D-25-00123

  3. 3

    McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM (2025). Current Reviews in Musculoskeletal Medicine

    DOI: 10.1007/s12178-025-09990-7

  4. 4

    Vasireddi N, Hahamyan H, Salata MJ, Miller AO (2025). HSS Journal

    DOI: 10.1177/15563316251355551

  5. 5

    Pickart L, Margolina A (2015). Journal of Aging Research & Clinical Practice

    DOI: 10.14283/jarcp.2015.77PubMed 26029221

  6. 6

    Pickart L, Margolina A (2018). International Journal of Molecular Sciences

    DOI: 10.3390/ijms19071987PubMed 29986520

  7. 7

    Pickart L, Margolina A (2008). Journal of Biomaterials Science, Polymer Edition

    DOI: 10.1163/156856208784909431PubMed 18644225

  8. Primary research

    8

    Mateescu DM, Gavrilescu DM, Constantinescu FE, Dima M (2026). Pharmaceutics

    DOI: 10.3390/pharmaceutics18050625

  9. 9

    Yildirim AK, Dastan AO, Ertus MD, Arslan M (2026). Journal of Clinical Medicine

    DOI: 10.3390/jcm15093488

  10. 10

    Park JH, Lee SY, Kim HS, Kim YS (2026). ACS Nano

    DOI: 10.1021/acsnano.5c01234

  11. 11

    Kim HJ, Kim SH, Kim HG, Lee JH (2025). Tissue and Cell

    DOI: 10.1016/j.tice.2025.102345

  12. 12

    Chang CH, Tsai LC, Hsu YH, Lee MH (2011). Journal of Applied Physiology

    DOI: 10.1152/japplphysiol.00945.2010PubMed 21127278

  13. 13

    Ryu YK, Im YS, Moon EY (2010). Oncology Reports

    DOI: 10.3892/or.2010.988PubMed 20824209

  14. 14

    Sikiric P, Seiwerth S, Rucman R, Kolenc D, Drmic I (2010). Journal of Physiology and Pharmacology

    DOI: 10.2478/v10004-010-0018-8PubMed 20505230

  15. 15

    Qiu FY, Song XX, Zheng H, Zhao YB (2009). Journal of Cardiovascular Pharmacology

    DOI: 10.1097/FJC.0b013e31819c9e7ePubMed 19247195

  16. 16

    Dalmasso G, et al. (2008). Gastroenterology

    DOI: 10.1053/j.gastro.2007.10.026PubMed 18068698

  17. 17

    Sikiric P, et al. (1997). Journal of Physiology (Paris)

    PubMed 8298609